2024-511453-22-00
Recruiting
Phase 1
A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants with Advanced Solid Malignancies
Kumquat Biosciences Inc.25 sites in 3 countries112 target enrollmentStarted: August 29, 2024Last updated:
Overview
- Phase
- Phase 1
- Status
- Recruiting
- Sponsor
- Kumquat Biosciences Inc.
- Enrollment
- 112
- Locations
- 25
Overview
Brief Summary
No summary available.
Eligibility Criteria
- Ages
- 18 years to 65+ years (65+ Years, 18-64 Years)
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Investigators
Regulatory Submissions
Scientific
Kumquat Biosciences Inc.
Study Sites (25)
Loading locations...
Similar Trials
Recruiting
Phase 1/2
A study to evaluate the safety and efficacy of the tumor-targeting human antibody-cytokine fusion protein L19TNF plus lomustine in patients with glioblastoma at first progression2022-501822-39-00Philogen S.p.A.113
Not yet recruiting
Phase 1
A Phase I study to evaluate the safety and efficacy of L19IL2 in combination with ruxolitinib in patients with advanced solid tumors.2025-522243-17-00Philogen S.p.A.96
Not yet recruiting
Phase 1
A study to evaluate the safety and tolerability of single ascending doses of AGMB-101 in healthy participants (Part A) and patients with liver cirrhosis (Part B).2024-515074-26-00AgomAb Therapeutics64
Completed
Phase 1
A Study to Evaluate the Safety and Tolerability of JNJ-77730614 When Given as Single and Multiple Doses to Healthy Participants to Assess How Long JNJ 77730614 Stays in the Body (Pharmacokinetics) and How the Body Responds to it (Pharmacodynamics)2023-505684-36-00Janssen - Cilag International92
Completed
Phase 1
Study to Evaluate the Safety and Efficacy of Treatment with NLM-001 before Standard Chemotherapy plus Zalifrelimab in Patients with Advanced Pancreatic Cancer2024-518852-22-00Nelum Corp.28